Univariate analysis for the probability of achieving a complete cytogenetic response on imatinib by 3 months of therapy
| Parameter . | Effect . | CCyR within 3 mo, median (range) or no. (%) . | P . | |
|---|---|---|---|---|
| Yes (n = 143) . | No (n = 109) . | |||
| Age, y | NS | 48 (15-79) | 48 (17-84) | .84 |
| Lower hemoglobin, g/dL | Adverse | 12.7 (8.8-16.7) | 12 (6.2-15.1) | < .001 |
| Higher WBC, ×109/L | Adverse (trend) | 24.5 (3.5-239.5) | 35.8 (2.2-283) | .06 |
| Platelets, ×109/L | NS | 372 (107-1476) | 356 (100-1413) | .71 |
| PB basophils, % | NS | 3 (0-19) | 4 (0-19) | .98 |
| Higher PB blasts, % | Adverse | 0 (0-3) | 0 (0-12) | < .001 |
| BM basophils, % | NS | 2 (0-8) | 3 (0-15) | .1 |
| Higher BM blasts, % | Adverse | 1 (0-13) | 2 (0-14) | .04 |
| Presence of splenomegaly | Adverse | 24 (17) | 44 (41) | < .001 |
| Presence of clonal evolution | NS | 4 (3) | 3 (3) | .99 |
| Longer CML duration, mo | Adverse | 0 (0-6) | 1 (0-12) | .06 |
| Dose (400 vs 800 mg/day) | Adverse | 18 (13) | 31 (29) | .001 |
| More than 90% Ph+ cells at start of therapy | Adverse | 130 (91) | 104 (96) | .09 |
| Sokal risk score | ||||
| Low | NS | 105 (73) | 57 (53) | .83 |
| Intermediate | NS | 33 (23) | 34 (31) | .83 |
| High | NS | 5 (4) | 17 (16) | .83 |
| Parameter . | Effect . | CCyR within 3 mo, median (range) or no. (%) . | P . | |
|---|---|---|---|---|
| Yes (n = 143) . | No (n = 109) . | |||
| Age, y | NS | 48 (15-79) | 48 (17-84) | .84 |
| Lower hemoglobin, g/dL | Adverse | 12.7 (8.8-16.7) | 12 (6.2-15.1) | < .001 |
| Higher WBC, ×109/L | Adverse (trend) | 24.5 (3.5-239.5) | 35.8 (2.2-283) | .06 |
| Platelets, ×109/L | NS | 372 (107-1476) | 356 (100-1413) | .71 |
| PB basophils, % | NS | 3 (0-19) | 4 (0-19) | .98 |
| Higher PB blasts, % | Adverse | 0 (0-3) | 0 (0-12) | < .001 |
| BM basophils, % | NS | 2 (0-8) | 3 (0-15) | .1 |
| Higher BM blasts, % | Adverse | 1 (0-13) | 2 (0-14) | .04 |
| Presence of splenomegaly | Adverse | 24 (17) | 44 (41) | < .001 |
| Presence of clonal evolution | NS | 4 (3) | 3 (3) | .99 |
| Longer CML duration, mo | Adverse | 0 (0-6) | 1 (0-12) | .06 |
| Dose (400 vs 800 mg/day) | Adverse | 18 (13) | 31 (29) | .001 |
| More than 90% Ph+ cells at start of therapy | Adverse | 130 (91) | 104 (96) | .09 |
| Sokal risk score | ||||
| Low | NS | 105 (73) | 57 (53) | .83 |
| Intermediate | NS | 33 (23) | 34 (31) | .83 |
| High | NS | 5 (4) | 17 (16) | .83 |
NS indicates not significant.